Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

Human Vaccines

Volumn 7, Issue 2, 2011, Pages 239-247

  Bermal, Nancy ^a   Huang, Li Min ^b   Dubey, Ashish P ^c   Jain, Hermant ^d   Bavdekar, Ashish ^e   Lin, Tzou Yien ^f   Bianco, Veronique ^g   Baine, Yaela ^g   Miller, Jacqueline M ^g  

^a Filinvest Corporate   (Philippines)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c MAULANA AZAD MEDICAL COLLEGE   (India)

^d MGM MC   (India)

^e KEM HOSPITAL   (India)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g GLAXOSMITHKLINE   (United States)

Author keywords

Adolescent; Bactericidal activity; Conjugate vaccine; Immunogenicity; Safety; Tetravalent meningococcal vaccine

Indexed keywords

MENINGITIS VACCINE; MENINGOCOCCAL ACWY TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INDIA; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PHASE 3 CLINICAL TRIAL; PHILIPPINES; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN REDNESS; SWELLING; TAIWAN; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; SEROTYPING; VACCINES, CONJUGATE;

EID: 79952467798     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.2.14068     Document Type: Article

References (31)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:51-63.
2. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91.
3. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23:274-9.
4. Soriano-Gabarro M, Wolter J, Ng T. Historical and emerging meningococcal disease in Asia [abstract]. World Congress of the World Society for Pediatric Infectious Diseases. Bangkok, Thailand 2007.
5. Nair D, Dawar R, Deb M, Capoor MR, Singal S, Upadhayay DJ, et al. Outbreak of meningococcal disease in and around New Delhi, India 2005-2006: a report from a tertiary care hospital. Epidemiol Infect 2009; 137:570-6.
6. World Health Organization. World Health Organization. Epidemic and pandemic alert an response (EPR). Meningococcal disease in the Philippines - update 2 2005 [Internet]. Available from: http://www.who.int/csr/don/2005-01- 28a/en/index.html.
7. Hossain MA, Ahmed D, Ahmed T, Islam N, Breiman RF. Increasing isolations of Neisseria meningitidis serogroup A from blood and cerebrospinal fluid in Dhaka, Bangladesh 1999-2006. Am J Trop Med Hyg 2009; 80:615-8.
8. Lu J, Lin F, Liu L, Li X, Li L. [Serum antibody level of meningococcal meningitis in health people in Hubei Province in 2003]. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25:996 (article in Chinese).
9. Ni JD, Jin YH, Dai B, Wang XP, Liu DQ, Chen X, et al. Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China. Postgrad Med J 2008; 84:87-92. (Pubitemid 351427574)
10. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679-83.
11. Chiou C, Liao J, Liao T, Li C, Chou C, Chang H, et al. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis 2006; 6:25.
12. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec 2002; 77:331-9.
13. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3. (Pubitemid 32043057)
14. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51:717-22.
15. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:1-10.
16. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity and immune memory of a novel meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13. (Pubitemid 41423328)
17. Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-53.
18. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8.
19. MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, et al. Social behavior and meningococcal carriage in British teenagers. Emerging Infect Dis 2006; 12:950-7. (Pubitemid 43848417)
20. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006; 134:556-66.
21. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece and Norway. J Clin Microbiol 2004; 42:5146-53.
22. Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, Deb M, et al. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerging Infect Dis 2007; 13:1614-6.
23. Suri M, Kabra M, Singh S, Rattan A, Verma IC. Group B meningococcal meningitis in India Scand. J Infect Dis 1994; 26:771-3.
24. Ayyagari A, Dubey ML, Bhandari SK. Sulphadiazine resistant strains of Neisseria meningitidis during an outbreak of meningococcal meningitis. Indian J Med Res 1987; 85:249-52.
25. Gopez I, Manoff S, White D, Dayrit M. Meningococcal disease outbreak in San Jose, Sipalay, Negros Occidental. Phil J Microbiol Infect Dis 1991; 20:17-22.
26. Wang J, Liu D, Yen J, Yu C, Liu H, Lin C, et al. Clinical features and outcome of sporadic serogroup W135 disease Taiwan. BMC Infect Dis 2006; 6:7.
27. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infec Dis J 2009; 28:86-91.
28. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4:156-67.
29. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005; 23:2222-7. (Pubitemid 40341456)
30. Centers for Disease Control and Prevention. Inadvertent misadministration of meningococcal conjugate vaccine - United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1016-7.
31. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4:316-9.